MALAT1 has previously been described as a metastasis-promoting long noncoding RNA (lncRNA). We show here, however, that targeted inactivation of the Malat1 gene in a transgenic mouse model of breast cancer, without altering the expression of its adjacent genes, promotes lung metastasis, and that this phenotype can be reversed by genetic add-back of Malat1. Similarly, knockout of MALAT1 in human breast cancer cells induces their metastatic ability, which is reversed by re-expression of Malat1. Conversely, overexpression of Malat1 suppresses breast cancer metastasis in transgenic, xenograft, and syngeneic models. Mechanistically, the MALAT1 lncRNA binds and inactivates the prometastatic transcription factor TEAD, preventing TEAD from associating with its co-activator YAP and target gene promoters. Moreover, MALAT1 levels inversely correlate with breast cancer progression and metastatic ability. These findings demonstrate that MALAT1 is a metastasis-suppressing lncRNA rather than a metastasis promoter in breast cancer, calling for rectification of the model for this highly abundant and conserved lncRNA.
L ong noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides with no protein-coding capacity 1 . The nuclear lncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) is among the most conserved lncRNAs and is highly abundant in normal tissues [2] [3] [4] . MALAT1 localizes to nuclear speckles 4 and has been shown on the basis of in vitro knockdown effects to modulate alternative pre-messenger RNA splicing 5 . However, Malat1-knockout mice showed no phenotypic differences compared with wild-type mice, and genetic ablation of Malat1 did not affect global gene expression, nuclear speckles, splicing factors, or alternative pre-mRNA splicing in mouse tissues 2, 6, 7 .
Previous in vitro and xenograft studies demonstrated contradictory effects of MALAT1 on tumor-cell growth and invasion [8] [9] [10] [11] [12] . Recently, mice were generated with a deletion of a 3-kb genomic region encompassing the 5′ end of Malat1 and its promoter 2 . After breeding these animals to transgenic mice that provide a model of breast cancer-MMTV (mouse mammary tumor virus)-PyMT (polyomavirus middle T antigen) 13 mice-a reduction in lung metastases was observed 14 , but the underlying mechanism remained unclear. Notably, this Malat1-deletion model exhibited substantial upregulation of Malat1's adjacent genes, including Neat1, Frmd8, Tigd3, Ehbp1l1, Ltbp3, and, to a lesser extent, Map3k11, Kcnk7, Fam89b, Scyl1, Slc25a45, Dpf2, and Cdc42ep2 (ref. 2 ). It is unknown whether their upregulation was due to the loss of Malat1 lncRNA or the deletion of regulatory sequences for these neighboring genes.
Questions have been raised as to whether phenotypes resulting from deleting a lncRNA-encoding gene can be unequivocally attributed either to the loss of the lncRNA per se or to the loss of overlapping regulatory elements 15 . A recent study revealed opposite effects from the gene deletion and insertional inactivation of the lncRNA Haunt, and the gene-deletion effect was attributed to the loss of Haunt genomic DNA 16 . Moreover, given the multiple examples of different or opposite phenotypes resulting from different strategies for inactivating the same lncRNA in vivo, it has been concluded that genetic rescue experiments from a separate transgene are crucial for separating lncRNA-specific effects from those arising from the manipulation of the underlying genomic DNA 15 . In addition to gene deletion, MALAT1 has been studied in experiments involving short hairpin RNA (shRNA) or small interfering RNA (siRNA), which is questionable for nuclear lncRNAs, and by means of antisense oligonucleotides (ASOs) in a few recent studies 14, 17, 18 . However, emerging evidence revealed substantial nonspecific effects of antisense RNAs and invalidated certain putative anticancer targets 19, 20 . The MALAT1 gene deletion, ASO and siRNA effects have never been validated to be MALAT1 specific through rescue experiments.
In this study, we observed that metastasis was induced by germline insertional inactivation or somatic knockout of Malat1 without alterations in the expression of adjacent genes, and we conducted genetic rescue experiments to demonstrate that this effect was specific to loss of Malat1 lncRNA. Moreover, we found that MALAT1 binds and inactivates TEAD and suppresses metastasis in a tumor cells (CTCs), we found that the percentages of CTCs in MMTV-PyMT;Malat1 −/− mice were significantly higher than those in MMTV-PyMT;Malat1 +/+ mice; this increase in CTCs was also reversed by genetic add-back of Malat1 (Fig. 1g,h) . Taken together, these data suggest that Malat1 suppresses the dissemination and lung metastasis of mammary tumor cells.
Given that the PyMT tumor and metastasis phenotypes of the FVB strain are stronger than those of the B6 strain 13, 22 , we used the FVB strain to further determine the effect of overexpressing Malat1. To this end, we backcrossed Malat1 Tg mice and Malat1 LSL controls to FVB mice for six generations, bred these mice to MMTV-PyMT mice on an FVB background, and confirmed that MMTV-PyMT;Malat1 Tg mice had a 3.2-fold increase in Malat1 levels in their mammary tumors relative to the levels in MMTV-PyMT;Malat1 LSL mice ( Fig. 2a ). In both groups, most females became moribund because of primary mammary tumor burdens between 12 and 13 weeks of age, and no significant difference in overall survival ( Supplementary Fig. 3d ), primary tumor weight ( Fig. 2b ), or tumor histology ( Supplementary Fig. 3e ) was found. By gross examination, MMTV-PyMT;Malat1 Tg mice had many fewer visible metastatic nodules in the lungs than did MMTV-PyMT;Malat1 LSL animals (P = 0.001; Fig. 2c,d ). We validated this observation by H&E staining (Fig. 2e ), which showed a pronounced reduction in lung metastases in MMTV-PyMT;Malat1 Tg mice, as gauged by the number of metastatic foci (P = 0.0007; Fig. 2f ) and the percentage of lung areas with metastatic lesions (P = 0.01; Fig. 2g ). Collectively, the targeted inactivation, restoration (rescue), and overexpression of Malat1 in genetic models demonstrate that Malat1 is a breast-cancer lung-metastasis suppressor.
Malat1 suppresses the metastatic ability of breast cancer cells.
To study the relevance of MALAT1 to human breast cancer, we first examined MALAT1 expression levels in a panel of human mammary epithelial or breast cancer cell lines. The non-transformed mammary epithelial cell line MCF10A showed much higher levels of MALAT1 than did all 12 breast cancer cell lines examined ( Fig. 3a) . Moreover, MALAT1 expression was much lower in basal-like, triple-negative breast cancer (TNBC) cells than in less aggressive/ metastatic luminal-like breast cancer cells ( Fig. 3a) , which we further confirmed using the Cancer Cell Line Encyclopedia (CCLE) 24 panel ( Fig. 3b ). Interestingly, a highly lung-metastatic subline of MDA-MB-231 breast cancer cells, named LM2 (ref. 25 ), showed lower MALAT1 expression than the weakly metastatic parental MDA-MB-231 cells ( Fig. 3a ).
Next, we studied the loss-and gain-of-function effects of MALAT1 on the metastatic ability of human breast cancer cells. It is difficult to target a nuclear lncRNA using shRNA or siRNA. Moreover, unlike protein-coding genes, lncRNAs cannot be depleted by single guide RNA (gRNA)-mediated frameshift mutations. Using a pair of MALAT1 gRNAs and a double-excision CRISPR knockout (DECKO) approach 26 (where CRISPR is clustered regularly interspaced short palindromic repeats), we deleted around 650 bp in the 5′ end of MALAT1 in luciferase-expressing MDA-MB-231 cells, and validated six MALAT1-deficient clones ( Supplementary Fig. 4a,b ). Whereas loss of MALAT1 did not affect the expression of adjacent genes ( Supplementary Fig. 4c ), cell proliferation ( Supplementary  Fig. 4d ), or anchorage-independent growth ( Supplementary Fig. 4e ), MALAT1-knockout clones showed higher migratory and invasive ability than control cells expressing GFP gRNA ( Supplementary  Fig. 4f ), an effect that was reversed by ectopic expression of mouse Malat1 ( Supplementary Fig. 4g ,h; mouse Malat1 was used because it is resistant to human MALAT1 gRNAs). Moreover, using time-lapse video microscopy, we observed a substantial increase in the speed of movement of MALAT1-knockout cells compared with control cells, which was reversed by Malat1 re-expression ( Supplementary  Fig. 4i and Supplementary Videos 1-3). To determine the effect of MALAT1 loss on lung metastatic colonization, we injected control cells (expressing GFP gRNA, which had similar metastatic behavior to the parental MDA-MB-231 cells; Supplementary Fig. 4j -l), MALAT1-knockout cells or Malat1-restored MDA-MB-231 cells into NSG (non-obese diabetic; severe combined immunodeficiency; interleukin-2 receptor gamma chain null) mice through the tail vein. Bioluminescent imaging of live animals ( Fig. 3c,d ) and whole lungs ( Fig. 3e ), as well as H&E staining of lung sections (Fig. 3f) , suggested that the knockout of MALAT1 in MDA-MB-231 cells strongly promoted lung metastasis in mice, and that this effect was fully reversed by restoration of Malat1 expression.
The lung-metastatic LM2 subline exhibited the lowest MALAT1 expression among all 13 cell lines examined ( Fig. 3a) . Stable transfection of luciferase-labeled LM2 cells with mouse Malat1 reduced cell movement, migration, and invasion ( Supplementary Fig. 5a -c and Supplementary Videos 4 and 5) without affecting cell proliferation ( Supplementary Fig. 5d ). Similarly, overexpression of Malat1 in HCC1806 and Hs578t human breast cancer cell lines inhibited motility and invasiveness ( Supplementary Fig. 5e -g). We performed tail-vein injection of LM2 cells into NSG mice. Bioluminescent imaging of live animals showed consistently less lung metastasis in recipients of Malat1-overexpressing LM2 cells ( Supplementary  Fig. 5h ,i). At week 5, mice that had received Malat1-overexpressing LM2 cells exhibited a 74% reduction in lung metastases relative to the control group ( Fig. 3g ), which was confirmed by histopathological analysis (Fig. 3h ). Similarly, stable transfection of 4T1 mouse mammary tumor cells with Malat1 ( Supplementary Fig. 5j ) markedly reduced their colonization of the lungs of syngeneic BALB/c mice, as gauged by live-animal imaging ( Supplementary Fig. 5k ,l), ex vivo lung imaging (Fig. 3i ), and the number of visible metastatic nodules ( Fig. 3j ). These data provide additional in vivo proof that MALAT1 suppresses the metastatic ability of human and mouse mammary tumor cells.
We next analyzed the RNA-seq data from The Cancer Genome Atlas (TCGA) 27 and found that MALAT1 was significantly underexpressed in human breast tumors compared with normal mammary tissues ( Supplementary Fig. 6a,b ). Using an Oncomine data-mining platform, we found that MALAT1 was substantially underexpressed in higher-grade breast tumors ( Supplementary Fig. 6c ), and that breast cancer metastases had lower MALAT1 expression than did primary mammary tumors ( Supplementary Fig. 6d ). In addition, Kaplan-Meier (KM) plotter 28 analysis showed that lower MALAT1 levels correlated with shorter distant metastasis-free survival both in total breast cancers and in luminal A and basal subtypes ( Supplementary Fig. 6e ).
To corroborate the observed correlation, we orthotopically implanted G418-resistant, luciferase-expressing 4T1 cells into syngeneic BALB/c mice, and isolated G418-resistant cells from mammary tumors and lungs. Interestingly, Malat1 levels were significantly lower in metastasized tumor cells than in paired primary tumor cells ( Supplementary Fig. 6f ). In addition, compared with 4T1 cells, the non-metastatic 67NR cell line and the weakly metastatic 168FARN and 4TO7 cell lines 29 showed higher Malat1 expression ( Supplementary Fig. 6g ). Taken together, these data demonstrate that higher MALAT1 levels are negatively associated with breast cancer progression and metastasis.
MALAT1 interacts with TEAD-family members. To elucidate the mechanism by which MALAT1 regulates metastasis, we attempted to identify its endogenous binding proteins by performing chromatin isolation by RNA purification coupled to mass spectrometry (ChIRP-MS) 30 . We collected the tumors from MMTV-PyMT mice and pulled down endogenous Malat1 lncRNA using mouse Malat1-specific, biotinylated DNA probes and streptavidin beads. DNA probes for U1 nuclear RNA and probe-free conditions were included as negative controls to validate the specificity of Malat1 pulldown (Fig. 4a ). Our ChIRP-MS analysis identified 970 Malat1interacting proteins, including previously reported Malat1 interactors such as splicing factors and RNA-binding proteins 5, 8, 9 . Most of them, however, interacted with both Malat1 and U1. Therefore, we screened for proteins specifically bound to Malat1 by excluding bound proteins in the two negative controls (U1 and probe-free beads). Only 23 out of 970 proteins met this criterion; among them, the Tead family stood out because all four Tead proteins were identified as Malat1's binding partners ( Supplementary Fig. 7a ).
Next, we performed western blot analysis of ChIRP samples, which validated the interaction between endogenous Malat1 and Tead proteins in both PyMT tumors ( Fig. 4b ) and 4T1 cells ( Fig. 4c ). Importantly, the interaction was abolished in Malat1null PyMT tumors, but was restored in tumors from the MMTV-PyMT;Malat1 −/− ;Malat1 Tg mutants ( Fig. 4b ), suggesting that this interaction is Malat1 RNA specific. In both PyMT tumors and 4T1 cells, Malat1 did not interact with the cytoplasmic marker Gapdh, the nuclear marker histone H3, or the Tead coactivator Yap (Fig. 4b,c ). , or from 4T1 cells (c), followed by immunoblotting with antibodies against pan-Tead, Yap, Gapdh, and histone H3 (HH3). d, RNA immunoprecipitation assay. Endogenous TEAD1 was immunoprecipitated from cross-linked MDA-MB-231 cells. TEAD1-bound MALAT1 was quantitated by qPCR with two primer sets. GAPDH was used as a negative control. e, RNA pulldown assay. Unlabeled and biotinylated Malat1 fragments (P1-P6) were synthesized by in vitro transcription, incubated with HEK293FT cell lysate, and pulled down with streptavidin beads. The bound proteins were eluted by boiling in Laemmli sample buffer and immunoblotted with antibodies against pan-TEAD, YAP, GAPDH, and histone H3. Btn: biotinylation. f, CLIP-qPCR assay of HeLa cells overexpressing HA-TEAD1 and mouse Malat1. The protected Malat1 RNA segments bound by TEAD1 were detected by qPCR using 69 pairs of primers. g, RNA immunoprecipitation assay. HeLa cells were transfected with HA-tagged full-length TEAD1 (FL), N-terminal region (NT), or transactivation domain (TAD), cross-linked, and subjected to immunoprecipitation with an HA-specific antibody. TEAD1-bound MALAT1 was quantitated by qPCR with two primer sets. All error bars are s.e.m. Uncropped blots are shown in Supplementary Fig. 10 .
To further corroborate our result, we pulled down TEAD1 protein from cross-linked MDA-MB-231, HeLa, BT549, or MDA-MB-468 human cells and isolated its associated RNAs. Reverse transcriptase (RT)-quantitative polymerase chain reaction (qPCR) analysis showed that MALAT1 lncRNA was highly enriched in TEAD1 immunoprecipitates ( Fig. 4d and Supplementary Fig. 7b ).
To identify the TEAD-binding region(s), we generated six nonoverlapping biotinylated Malat1 fragments (P1-P6; 1.1-1.2 kb each) spanning full-length mouse Malat1 by in vitro transcription. All six fragments, but not U1, bound to TEAD proteins ( Fig. 4e and Supplementary Fig. 7c,d ), suggesting that the TEAD-binding sites may be distributed diffusely on Malat1 lncRNA. By contrast, GAPDH, YAP, and histone H3 did not interact with any region of Malat1 (Fig. 4e ), validating the specificity of the Malat1-TEAD binding. To further map the TEAD-binding sites on Malat1, we performed a UV cross-linking-immunoprecipitation and qPCR (CLIP-qPCR) assay 31, 32 using 69 pairs of primers with overlapping 200-bp amplicons, which allowed detection of the protected Malat1 RNA segments bound by TEAD1 and the mapping of TEAD1-binding sites on Malat1 at 200-nucleotide intervals ( Supplementary Fig. 7e ). At a threshold enrichment value of 2, all six fragments (P1-P6) showed multiple peaks; at a threshold enrichment value of 10, each of the six fragments showed at least one major peak and a total of ten major peaks were detected ( Fig. 4f ), suggesting that Malat1 contains multiple TEAD-binding sites.
We sought to identify the Malat1-binding domain on TEAD1. TEAD1 consists of two functional regions: the N-terminal region (NT) containing the TEA domain responsible for DNA binding, and the C-terminal transactivation domain responsible for YAP binding 33 ( Supplementary Fig. 7f ). Accordingly, we generated two TEAD1 truncation mutants ( Supplementary Fig. 7f,g) and performed RNA immunoprecipitation. Interestingly, Malat1 was enriched in the immunoprecipitates of full-length TEAD1 or the transactivation domain, but not in the immunoprecipiates of the N-terminal region (Fig. 4g ), suggesting that Malat1 interacts with TEAD1's transactivation domain-the same domain that mediates the YAP-TEAD1 interaction 33 .
MALAT1 inhibits the transcriptional activity of TEAD. The TEAD transcription factors and their coactivators YAP and TAZ promote tumor progression and metastasis through transcriptional activity 34 . In the nucleus, TEAD proteins interact with YAP or TAZ to activate the expression of target genes, including the classical TEAD targets CTGF, CYR61, ANKRD1, AMOTL2, AJUBA, AXL, and WTIP [35] [36] [37] [38] . We investigated whether MALAT1 regulates TEAD's transcriptional activity. Indeed, ectopic expression of Malat1 reduced, while knockout of MALAT1 increased, the activity of a TEAD luciferase reporter containing tandem TEADbinding sites 39 (Fig. 5a,b ). However, fractionation assays and immunofluorescent staining demonstrated that TEAD proteins were localized exclusively in the nucleus of both control and MALAT1knockout MDA-MB-231 cells ( Supplementary Fig. 7h,i ), suggesting that MALAT1 does not affect the nuclear localization of the TEAD proteins.
Because MALAT1 RNA is highly abundant 2 , and because the TEAD-binding sites are distributed throughout MALAT1 (Fig. 4e,f) , we speculated that MALAT1 may sequester TEAD, thereby blocking TEAD's ability to bind YAP and/or the target genes. To test this hypothesis, we first performed co-immunoprecipitation of TEAD1 and YAP. Upon Malat1 overexpression, we observed a clear reduction in YAP-TEAD1 interaction (Fig. 5c,d ). Next, we analyzed YAP-TEAD target gene promoters by chromatin immunoprecipitation (ChIP) assays. Ectopic expression of Malat1 in LM2 cells significantly decreased the occupancy of three classical target gene (ANKRD1, CTGF, and CYR61) promoters by endogenous TEAD1 or YAP ( Supplementary Fig. 8a) ; conversely, in MALAT1-knockout MDA-MB-231 cells, the occupancy of these three gene promoters by endogenous TEAD1 or YAP was prominently increased (Fig. 5e ).
YAP is a transcriptional co-factor that lacks a DNA-binding domain, and TEAD proteins mediate YAP's association with chromatin 40 . Importantly, MALAT1 does not bind YAP (Fig. 4b,c,e ). To further exclude the possibility that MALAT1 directly regulates YAP, we generated GAL4 DNA-binding-domain (DBD)-fused YAP constructs (that is, TEAD-independent YAP mutants capable of binding to DNA without TEAD) and gauged their transcriptional activity using a GAL4 DBD-responsive luciferase reporter. When fused to the GAL4 DBD, both full-length YAP and its transactivating domain exhibited substantial transcriptional activity, which was not altered by overexpression of Malat1 ( Supplementary Fig. 8b ). This suggests that repression of YAP-TEAD's transcriptional activity by Malat1 is TEAD dependent.
We examined whether YAP-TEAD target gene expression is regulated by MALAT1. Indeed, in Malat1-overexpressing LM2 cells, the expression of four of seven classical target genes examined was significantly repressed ( Supplementary Fig. 8c ). Conversely, these target genes were upregulated in MALAT1-knockout clones of MDA-MB-231 cells ( Supplementary Fig. 8d ). Notably, compared with control PyMT mouse mammary tumors, Malat1-deficient PyMT tumors showed an increase in expression levels of these classical YAP-TEAD target genes, an effect that was reversed by genetic add-back of Malat1 (Fig. 5f) .
To determine the functional relevance to metastasis, we used shR-NAs to knock down multiple TEAD-family members 41 in MALAT1knockout MDA-MB-231 cells (Fig. 5g) . Notably, depletion of TEAD proteins reversed the migration, invasion, and in vivo metastasis (Fig. 5h-j and Supplementary Fig. 8e-g) induced by the loss of MALAT1, with only a marginal inhibitory effect on migration and invasion of control MDA-MB-231 cells ( Supplementary Fig. 8f,g) , suggesting that the metastasis-promoting effect of MALAT1 depletion is TEAD dependent. Conversely, overexpression of Malat1 in LM2, BT549, and SUM149 cells decreased migration and invasion, which was reversed by TEAD1 overexpression ( Supplementary  Fig. 8h ,i), suggesting that Malat1 inhibits cell motility and invasiveness through TEAD.
ITGB4 and VEGFA are TEAD-target genes regulated by MALAT1. In addition to validating that known TEAD-target genes are downregulated by MALAT1, we sought to identify novel MALAT1regulated genes. To this end, we performed RNA-seq analysis and identified nine genes that were most substantially upregulated in MMTV-PyMT;Malat1 −/− tumors, compared with both MMTV-PyMT;Malat1 +/+ tumors and MMTV-PyMT;Malat1 −/− ;Malat1 Tg tumors (Fig. 6a ). We also performed metastasis-gene-specific qPCR array analysis and identified three genes that were most substantially downregulated in Malat1-overexpressing LM2 cells (Supplementary Table 1 ). Two of these 12 Malat1-downregulated genes, Itgb4 and Vegfa, are well-established metastasis promoters and have been shown to be bound by YAP-TEAD 42 . In addition, from the pairedend RNA-seq analysis, we found that only 51 out of 16,034 cassette exons (0.3%) exhibited significant changes in the splicing pattern in Malat1-knockout PyMT tumors compared with Malat1 wild-type PyMT tumors ( Supplementary Fig. 9a ). Thus, Malat1 has little effect on global pre-mRNA splicing.
ITGB4 encodes integrin β 4, which forms a heterodimer with integrin α 6 to promote tumor progression and to direct lung-tropic metastasis [43] [44] [45] [46] . VEGFA encodes vascular endothelial growth factor, a promoter of angiogenesis and metastasis 47 . By RT-qPCR analysis, we confirmed that ITGB4 and VEGFA mRNA levels were significantly upregulated by the loss of Malat1 both in PyMT tumors ( Fig. 6b ) and in MDA-MB-231 cells (Fig. 6c) , while re-expression of Malat1 in MMTV-PyMT;Malat1 −/− mice ( Fig. 6b ) and in MALAT1knockout MDA-MB-231 cells (Fig. 6c ) reversed the induction of Supplementary Fig. 10 .
ITGB4 and VEGFA expression. Moreover, ectopic expression of Malat1 in LM2 cells reduced ITGB4 and VEGFA levels (Fig. 6c ). We next investigated whether the expression of ITGB4 and VEGFA is activated by TEAD and whether Malat1 opposes it. By testing a series of upstream regulatory regions of the human ITGB4 or VEGFA gene cloned into a luciferase-reporter vector 48, 49 , we identified two regions, named L7 and V1 respectively, as the minimal promoter/enhancer regions of ITGB4 and VEGFA that are responsive to TEAD ( Supplementary Fig. 9b-d) . Next, using the luciferase construct containing the L7 or V1 region, we found that overexpression of Malat1 suppressed the transcriptional activity of ITGB4 and VEGFA promoters both at the basal level and upon TEAD1 overexpression (Fig. 6d ). VEGFA is a secreted protein, and ELISA assays showed that secreted VEGFA was upregulated by MALAT1 depletion in MDA-MB-231 cells and was downregulated by Malat1 overexpression in LM2 cells (Fig. 6e ). Furthermore, ChIP assays showed that knockout of MALAT1 increased (Fig. 6f) , while overexpression of Malat1 reduced ( Supplementary Fig. 9e ), the occupancy of the ITGB4 and VEGFA promoters by TEAD1 and YAP. Taken together, these data demonstrate that ITGB4 and VEGFA are TEAD-target genes and are negatively regulated by MALAT1.
VEGFA is known for its function in angiogenesis 50 . Moreover, tumor cells respond to autocrine and paracrine VEGFA signals through their VEGF receptor tyrosine kinases and neuropilins 47, [51] [52] [53] [54] , and autocrine VEGFA signaling stimulates cancer-cell migration and invasion 47, 52, 54 . Indeed, we found that recombinant human VEGFA 165 (the most abundant isoform) 53 promoted invasion by MDA-MB-231 cells ( Supplementary Fig. 9f ). Furthermore, knockdown of VEGFA in MALAT1-knockout MDA-MB-231 cells reversed the induction of cell invasiveness ( Supplementary  Fig. 9g-i) . Thus, VEGFA may be a functional YAP-TEAD target that is upregulated by MALAT1 depletion.
Discussion
Using both genetically engineered mouse models and xenograft models, we have found that MALAT1 overexpression inhibits, while MALAT1 deficiency induces, breast cancer metastasis; the effect of MALAT1 deficiency can be reversed by adding back this lncRNA. We have also found that MALAT1 sequesters the transcription factor TEAD, leading to inhibition of TEAD's transcriptional activity. Although our findings represent a big departure from the literature, our approaches are highly rigorous. There is no evidence that the previously reported Malat1 gene deletion or ASO/siRNA phenotype was specific to loss of Malat1 lncRNA. By contrast, several critical considerations have been taken into account in our study. First, we used a transcriptional terminator insertion strategy that inactivates the Malat1 gene without altering the expression of its neighboring genes, rather than deleting a genomic region of several kilobases and thereby causing the upregulation of multiple genes adjacent to Malat1. Second, we conducted genetic rescue experiments to demonstrate that the metastasis induction by MALAT1 germline insertional inactivation or somatic knockout was specific to loss of MALAT1 lncRNA. Third, we found that overexpression of Malat1 suppressed breast cancer metastasis in transgenic, xenograft, and syngeneic models. Fourth, we used either a B6 or an FVB background (instead of a mixed background) for all compound mouse mutants, which is crucial for breast cancer models. Mechanistically, we captured an endogenous MALAT1-TEAD interaction in primary mammary tumors, and discovered that MALAT1 binds and inactivates the prometastatic transcription factor TEAD. Taken together, our results reveal the unexpected function of MALAT1 through comprehensive targeted inactivation, restoration (rescue), and overexpression approaches in multiple in vivo models. Our findings highlight a need to reassess ongoing efforts to target MALAT1 as an antimetastatic therapeutic strategy, and provide a general framework for rigorous characterization of lncRNAs.
URLs. Howard Chang's laboratory protocol, http://changlab.stanford. edu/RNA_pull-down_assay.pdf; Quantas Documentation, https:// zhanglab.c2b2.columbia.edu/index.php/Quantas_Documentation; Cancer Cell Line Encyclopedia, https://portals.broadinstitute.org/ ccle; Oncomine data-mining platform, https://www.oncomine.org; Gene Expression Omnibus, https://www.ncbi.nlm.nih.gov/geo/; Kaplan Meier Plotter, http://kmplot.com/analysis/.
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Methods
Mouse models. The 7-kb full-length mouse Malat1 gene (NR_002847), including a 47-bp upstream genomic sequence and 19-bp downstream genomic sequence, was cloned into the pGEM-T vector (Promega, number A362A) and then subcloned into the RMCE (recombinase-mediated cassette exchange) vector ( Supplementary  Fig. 3a) . The subsequent generation of targeted Malat1 transgenic mice was performed at Taconic (see Supplementary Note for details).
Malat1-knockout mice with targeted disruption of Malat1 (Malat1 −/− ) were from S. Nakagawa's lab stock. We bred MMTV-PyMT males (on a C57BL/6 background, provided by W. Muller, McGill University, Canada) to Malat1 −/− females, and then further bred MMTV-PyMT;Malat1 +/− males to Malat1 +/− females to obtain MMTV-PyMT;Malat1 −/− mice. To restore Malat1 expression in MMTV-PyMT;Malat1 −/− mice, we bred Malat1 −/− mice to Malat1 Tg mice and further mated their offsprings to produce Malat1 −/− ;Malat1 Tg mice. MMTV-PyMT;Malat1 −/− males were then bred to Malat1 −/− ;Malat1 Tg females to obtain MMTV-PyMT;Malat1 −/− ;Malat1 Tg triple mutants. All mice described here were on a C57BL/6 background.
To generate Malat1 Tg animals on an FVB/N background, we backcrossed Malat1 Tg mice on C57BL/6 to FVB/N mice for six generations. Then Malat1 Tg females on FVB/N were bred to MMTV-PyMT males on FVB/N (The Jackson Laboratory, stock #002374) to produce MMTV-PyMT;Malat1 Tg mice. MMTV-PyMT;Malat1 LSL mice were generated and used as the control.
Genotyping of MMTV-PyMT transgenic mice and Malat1-knockout mice was performed as described 7, 23 . Primer sequences for PCR genotyping are listed in Supplementary Table 2 . The purity of all mouse strains used in this study is greater than 98%. Tumor and metastasis studies in GEM models. All animal studies were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center. Mammary-tumorfree survival was determined by palpation. Mice were euthanized when they met the institutional euthanasia criteria for tumor size (2 cm in diameter) or overall health condition. MMTV-PyMT;Malat1 +/+ , MMTV-PyMT;Malat1 −/− , and MMTV-PyMT;Malat1 −/− ;Malat1 Tg female mice on a C57BL/6 background were euthanized at 13, 16, and 19 weeks of age and at the endpoint (20-25 weeks of age, upon euthanasia notice). MMTV-PyMT;Malat1 LSL and MMTV-PyMT;Malat1 Tg female mice on an FVB/N background were euthanized at 8 weeks of age and at the endpoint (12-13 weeks of age, upon euthanasia notice). Whole mammary glands or tumors and lung tissues were collected, weighed, and processed for histopathological analysis. Lung metastases were analyzed by gross examination of freshly dissected lungs and histopathological review of H&E-stained lung sections.
Circulating tumor cell isolation and staining. Around 150 μ l of peripheral blood was collected from live animals via retro-orbital bleeding, and red blood cells were lysed with red blood cell (RBC) lysis buffer (Gibco, number A10492-01). Nucleated cells were spun onto glass slides using Cytospin and fixed in 10% formalin. For immunofluorescent staining of the PyMT protein, fixed cells were permeabilized with 0.25% Triton X-100 in phosphate-buffered saline (PBS). Endogenous peroxidase was blocked with 1.5% H 2 O 2 in 0.05% Tween-20 in PBS (PBST). The cells were then incubated with a PyMT-specific primary antibody (Abcam, number ab15085, 1/200) and horseradish peroxidase conjugated anti-rat secondary antibody (Vector laboratories, PI-9401, 1/500). The signal was amplified using a tyramide signal amplification kit (Perkin Elmer, NEL741001KT). Stained slides were mounted with VECTASHIELD antifade mounting medium with DAPI (Vector Laboratories, H-1200). For CTC quantification, the ratio of PyMT + ;DAPI + cells to total DAPI + cells was calculated.
Experimental metastasis assays. Tumor cells were injected into the tail vein of 6-to 8-week-old female mice: NSG mice were injected with 2 × 10 5 MDA-MB-231 cells or 1 × 10 5 LM2 cells, and BALB/c mice were injected with 5 × 10 5 4T1 cells. Metastasis was monitored by luciferase imaging of live animals using an IVIS-200 bioluminescence imaging system (Perkin Elmer) after intraperitoneal injection of 100 μ l d-luciferin substrate (25 mg ml −1 in PBS, Perkin Elmer). Mice were euthanized when they met the institutional euthanasia criteria for overall health condition. The lungs were collected, imaged with d -luciferin substrate (150 μ g ml −1 in PBS), and then processed for histopathological analysis.
Immunoblotting. Cells were lysed in RIPA lysis buffer (Millipore) containing protease inhibitors and phosphatase inhibitors (GenDEPOT). Proteins were resolved on 4− 20% precast gradient gels (Bio-Rad) and transferred to a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% non-fat milk in Tris-buffered saline with 0.05% Tween-20 (TBST), membranes were incubated with the primary antibody followed by the secondary antibody conjugated with horseradish peroxidase. After washing, the bands were visualized with enhanced chemiluminescence substrate (Denville). Primary antibodies used are as follows: antibodies against pan-TEAD (1/1,000, Cell Signaling Technology, 13295), FLAG (1/5,000, Sigma, F7425), hemagglutinin (HA; 1/2,000, Santa Cruz Biotechnology, sc-7392), cyclophilin B (1/5,000, ThermoFisher Scientific, PA1-027A), YAP (1:1,000, Cell Signaling Technology, 14074), histone H3 (1/1,000, Cell Signaling Technology, 9715), lamin B1 (1/1,000, Cell Signaling Technology, 12586), α -tubulin (1/1,000, Sigma, T5168), heat-shock protein (HSP)90 (1/5,000, BD Biosciences, 610419), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1/1,000, ThermoFisher Scientific, MA5-15738).
Lentiviral vectors and lentivirus production. Lentiviral vectors containing a pair of gRNAs targeting human MALAT1 (pDECKO_MALAT1_C, Addgene number 72622) 26 and CRISPR-associated protein 9 (Cas9; lentiCas9-Blast, Addgene #52962) 55 were from Addgene. Two shRNAs targeting TEAD1/3/4 (ref. 41 ) were cloned by restriction enzymes AgeI and EcoRI into the pLKO.1-neo vector (Addgene number 13425). The FU-luciferase-CRW/RFP vector was from L. Xin (Baylor College of Medicine, Houston, TX, USA). HEK293FT cells were co-transfected with the lentiviral vector, an envelope plasmid (pCMV-VSV-G, Addgene number 8454), and a packaging plasmid (pCMV-dR8.2 dvpr, Addgene number 8455) 56 . Two days post transfection, viral supernatant was harvested, filtered through a 0.45-μ m filter, and added to target cells.
Malat1 overexpression and CRISPR-Cas9-based MALAT1 knockout. MDA-MB-231 and 4T1 cells were infected with the FU-luciferase-CRW/RFP lentivirus and sorted by red fluorescent protein (RFP). Luciferase-labeled MDA-MB-231 cells were then infected with the lentiCas9-Blast lentivirus and selected with blasticidin (10 μ g ml −1 ). Surviving cells were infected with the pDECKO_MALAT1_C lentivirus and selected with puromycin (1.5 μ g ml −1 ). After selection, single cells were plated in 96-well plates using a flow cytometer and grown for one to two weeks. The isolated single clones were subjected to qPCR, PCR, and DNA sequencing for knockout validation. DNA-sequencing results showed that nucleotides 871-1,539 and 857-1,539 of MALAT1 were deleted in KO1 and KO2 (the two knockout clones used for functional assays), respectively. For qPCR of MALAT1, we used the MALAT1 TaqMan probe (ThermoFisher Scientific, Hs00273907_s1) and five sets of qPCR primers, including four previously described sets 26 (primer sequences are listed in Supplementary Table 2 ). We used gRNAs targeting GFP (pDECKO_GFP, Addgene, 72619) as control gRNAs and the control cells were bulk population. To restore Malat1 in MALAT1-knockout MDA-MB-231 cells and to overexpress Malat1 in LM2 and 4T1 cells, we subcloned fulllength mouse Malat1 from the pGEM-T vector to the pcDNA3.1(-)-hygro vector, and transfected it into cells using Lipofectamine 2000 (Invitrogen). Three days post transfection, hygromycin (300 μ g ml −1 for LM2 and 800 μ g ml −1 for 4T1) was added to select for stable cell lines.
Chromatin isolation by RNA purification. The procedure was adapted and modified from a previous publication 57 . Buffers (lysis buffer, hybridization buffer, wash buffer, and RNA proteinase K buffer) were used as described 57 . Mammary tumors from MMTV-PyMT female mice were collected and frozen in liquid nitrogen. Around 300 mg of frozen tumor tissues were pulverized using a sample pulverizer (Covaris). Cells or pulverized tissues were cross-linked in 4% formaldehyde in PBS by inverting at room temperature for 30 min. The crosslinking reaction was quenched with 1/10 volume (0.125 M) of 1.25 M glycine at room temperature for 5 min. After centrifugation and removal of the supernatant, the pellet was washed with chilled PBS, resuspended in lysis buffer containing protease inhibitors (GenDEPOT), phenylmethylsulfonyl fluoride (PMSF; 1 mM), and RNase inhibitor (Ambion), and sonicated. After centrifugation of sonicated samples, the supernatant was precleared twice with streptavidin beads (Invitrogen) by shaking at 37 °C for 30 min. 1% of pre-cleared lysate was saved for RNA and protein input. 1 μ l 3′ -biotinylated DNA probes (100 μ M of 32 Malat1 probes or a probe for U1 or GFP; see probe sequences in Supplementary Table 3 ) was added to 1 ml lysate, and then a 2× lysate volume of hybridization buffer containing protease inhibitors, PMSF (1 mM), and RNase inhibitor was added to the lysate. Hybridization was performed at 37 °C with shaking overnight. Next day, streptavidin beads were added to the hybridization reaction and incubated at 37 °C with shaking for 30 min (100 μ l beads per 100 pmole probes). After five washes, the beads were resuspended in wash buffer. A 1/10 volume was transferred to a new tube for RNA isolation and a 9/10 volume was used for protein elution. Wash buffer was removed from the tube containing a 9/10 bead volume.
data sets associated with published papers. To compare tumors of different sites, we applied a threshold P value of 0.05 to screen data sets associated with published papers. Original data sets were downloaded and an unpaired t-test was performed on the relative expression level (log2 median-centered intensity). To assess the correlation of MALAT1 expression with clinical outcomes, we used the KM plotter 28 and performed a log-rank test to compare high and low expression groups. To examine the expression of genes adjacent to Malat1 in the Malat1-knockout mouse model used in this study, we used the microarray data (downloaded from the NCBI Gene Expression Omnibus under code GSE37707) from a previous study 7 .
Statistical analysis. The experiments were repeated two to three times. Unless otherwise noted, data are presented as means ± s.e.m., and a two-tailed t-test (unpaired or paired, as indicated) was used to compare two groups of independent samples. The log-rank test was used to compare KM survival curves. Statistical methods used for RNA-seq analysis and TCGA data analysis were described above. P < 0.05 was considered statistically significant. Corresponding author(s): Li Ma Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
No computer code was used.
Data analysis
We used Proteome Discoverer 2.0 Mascot engine (ThermoFisher Scientific) for mass spectrometric analysis; Living Image® software (Perkin Elmer, for the Xenogen IVIS-200 imaging system) for bioluminescent image analysis; JASPAR for analysis of transcription factor (TEAD) binding sites on target genes; OLego and Quantas for RNA splicing pattern analysis; and Imaris image analysis software for live imaging analysis.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
